Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12512MR)

This product GTTS-WQ12512MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12512MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3792MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ7846MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ8817MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ1943MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ1866MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8760MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ14694MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ8978MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW